This marks the first dedicated transcatheter heart valve approved for high-risk patients with symptomatic severe AR.

The FDA PMA for JenaValve's Trilogy device for TAVR-AR comes months after a court struck down Edwards Lifesciences attempt to ...

JenaValve has secured the FDA’s approval for its minimally invasive heart implant, making it the first to claim a U.S. green ...

JenaValve announced today that it has received FDA premarket approval (PMA) for its Trilogy transcatheter heart valve system.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket ...

IRVINE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the ...

The approval comes two months after Edwards Lifesciences scuttled plans to buy JenaValve for $945 million amid opposition ...

JenaValve's Trilogy System, FDA-approved for severe AR, offers secure anchoring without calcium. It is a breakthrough for ...

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, showcased 2-year follow up data from ...

JenaValve Technology just added another $26.5 million to its expanding Series C round, which looks to have swelled to near $100 million. The financing round was led by RMM and Valiance, and included ...

IRVINE, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the appointment of John ...

MUNICH, & IRVINE, Calif.--(BUSINESS WIRE)--JenaValve Technology, Inc., a developer, manufacturer and marketer of next-generation transcatheter aortic valve repair (TAVR) systems for the treatment of ...